Turning point., page-6

Well, let’s hope we are successful with it. The science seems very sound.
For me, the negative is the extremely long development time required, which translates into higher opportunity cost to hold it. (If only I’d sold at 20c I could have bought back in now!)
It’s another 18 months at least until dosing for Phase 1 even commences. I’m not sure the SP will have any reason to head north prior to that.
Unless, of course a buyout offer is made. Even that will a lowball. (No-one in their right mind makes a high offer initially.)